Safe Pro to Capitalize on Landmark Proposed FAA Rules Normalizing Drone Operations Utilizing Beyond Visual Line of Sight with Expanded AI-Powered Drone Services

FAA’s Proposed Rules to normalize Beyond Visual Line of Sight (BVLOS) operations can unlock transformative scaled drone applications across key sectors allowing for accelerated deployment of Safe Pro’s Artificial Intelligence technology

AVENTURA, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — via IBNSafe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a leader in artificial intelligence (AI)-powered defense and security solutions today applauded efforts by the Department of Transportation and Federal Aviation Administration’s (FAA) proposed rules for normalizing Beyond Visual Line of Sight (BVLOS) drone operations, eliminating a previously time consuming and burdensome regulatory process.

The FAA proposal envisions that drones would have technologies, such as Artificial Intelligence-powered object detection, that enable them to automatically detect and avoid other cooperating aircraft. The Company expects this landmark proposal will expand the use of its AI-powered computer vision and object detection technologies and accelerate the deployment of such AI-powered drone systems for government, public, and private customers.

According to the Commercial Drone Alliance, the proposed action to normalize BVLOS operations in the National Airspace System will unlock transformative scaled drone applications across key sectors such as agriculture, energy, public safety, emergency response, infrastructure inspection, and logistics. Prior to the new rules proposal, according to Fact.MR analysis, the drone services market had an estimated value of $8.66 billion in 2025 and was expected to grow at a CAGR of 14.3%, reaching an estimated $32.96 billion by 2035.

“We created Safe Pro to harness drones and AI to enable customers in defense, humanitarian aid, law enforcement and a wide array of commercial markets to quickly gain access to critical information and improve situational awareness. It is our belief that streamlined regulations and new rules such as those supporting safe, BVLOS operations, will enable us to advance our ongoing efforts to introduce innovative, AI-powered drone-based services capable of delivering tremendous value to customers,” said Dan Erdberg, Chairman and CEO of Safe Pro Group.

The newly proposed rules, subject to revision following public comment, would enable greater operational flexibility for operators as well as drone and UAS manufacturers with the goal of safely normalizing BVLOS drone operations. This would include detailed requirements for operations, aircraft manufacturing, keeping drones safely separated from other aircraft, operational authorizations and responsibility, security, information reporting and record keeping. The Company believes that these new rules will enable rapid growth in the drone services sector and support its efforts to create a wide array of new AI-powered drone services ranging from providing enhanced public safety at large outdoor events to supporting wildlife conservation and environmental protection efforts.

Safe Pro’s Airborne Response unit is one of Florida’s top providers of drone-based critical infrastructure inspections, trusted by utilities, telecoms, and insurers for real-time, mission-critical insights. Its role in hurricane preparedness and recovery also positions Safe Pro as an essential partner in climate resilience. It currently operates a fleet of advanced, U.S. government-approved drone platforms for both “Blue Sky” normal business operations as well as “Gray Sky” rapid incident management and disaster response operations. The Company is currently working to integrate the AI-powered computer vision technologies of its Safe Pro AI unit into Airborne Response services in support of an array of new drone-based applications developed for public safety, critical infrastructure inspection and environmental protection.

Safe Pro’s patented AI-powered computer vision technology is designed to rapidly analyze drone-based imagery to detect small objects. It has been battle-tested in Ukraine for nearly 3 years where it is being used to detect and identify over 150 types of landmines and unexploded ordnance in a fraction of a second per image, rapidly delivering mission-critical situational awareness. Whether deployed on the edge in real-time (SpotlightAITM OnSite) or leveraging Amazon Web Services (AWS) on the cloud (SpotlightAITM), the Company’s Safe Pro Object Threat Detection (SPOTD) technology can scale globally, offering solutions for rapid battlefield analysis as well as supporting large-scale commercial and humanitarian demining operations. Powering the Company’s SPOTD technology, Safe Pro’s unique real-world datasets include high-resolution drone imagery and GPS-tagged geospatial data encompassing over 1.66 million drone images analyzed to date, and 28,000+ threats identified across 6,705 hectares in Ukraine, an area nearly equivalent in size to Manhattan.

For more information about Safe Pro Group, its subsidiaries, and technologies, please visit https://safeprogroup.com and connect with us on LinkedIn, Facebook, and X.


About Safe Pro Group Inc.


Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. It is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing leveraging commercially available “off-the-shelf” drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosives threats, providing a much safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform is targeting multiple markets that include commercial, government, law enforcement and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.

For more information on Safe Pro Group Inc., please visit https://safeprogroup.com

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements including the Company’s filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations:

Brett Maas, Managing Partner
Hayden IR (646) 536-7331
[email protected]

Corporate Communications / Media Relations:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
(512) 354-7000
[email protected]  



Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

PR Newswire

Proposed merger anticipated to close in 2025

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small or large molecule drugs to the lungs by inhalation


FRAMINGHAM, Mass.
, Aug, 6, 2025 /PRNewswire/ — Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced second quarter financial results for 2025 and provided a corporate update.

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, “Our focus in the second quarter has been to advance steps to complete the proposed merger with Cullgen, a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies for the treatment of pain, cancer and other diseases. During the quarter, the SEC declared our registration statement effective and our stockholders approved the Merger, which will be completed subject to certain closing conditions, including approval from Nasdaq and the China Security Regulatory Commission. If consummated, the proposed merger would create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain. As part of the proposed merger, Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.”


Proposed Merger with Cullgen

As previously reported, on November 13, 2024, the Company entered into an agreement and plan of merger with Cullgen Inc. (“Cullgen”), PCL Merger Sub, Inc. and PCL Merger Sub II, LLC, as amended by Amendment No. 1 thereto on April 7, 2025 (the “Merger Agreement” and such transaction, the “Merger”).

Additional information about the Merger Agreement and proposed Merger was previously disclosed in a registration statement on Form S-4 (File No. 333-284993) initially filed with the Securities and Exchange Commission (the “SEC”) on February 14, 2025, as amended on April 17, 2025, and May 7, 2025, and declared effective on May 9, 2025.

On June 16, 2025, the Company held a special meeting in lieu of the annual meeting of Pulmatrix stockholders, at which the Company’s stockholders approved the Merger and related proposals. The Closing is subject to other customary closing conditions, including Nasdaq’s approval of the listing of the shares of Pulmatrix common stock to be issued in connection with the Merger and approval from the China Security Regulatory Commission.

The proposed Merger is anticipated to close in 2025, subject to the satisfaction of the aforementioned closing conditions, among others, however the exact timing of the consummation of the proposed Merger cannot be predicted. If the proposed Merger is completed, the business of Cullgen will continue as the business of the combined company.

Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ Technology


iSPERSE™ Technology

  • iSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases.
  • As of June 30, 2025, Pulmatrix’s patent portfolio related to iSPERSE™ included approximately 146 granted patents, 18 of which are granted U.S. patents, and approximately 54 additional pending patent applications in the U.S. and other jurisdictions.


PUR3100

  • PUR3100 is an orally inhaled dihydroergotamine (“DHE”) engineered with Pulmatrix’s iSPERSE™ dry powder inhalation technology for the treatment of acute migraine.
  • In 2023, Pulmatrix announced the Food and Drug Administration’s acceptance of an Investigational New Drug (“IND”) application for PUR3100 and receipt of a “study may proceed” letter to proceed with a Phase 2 study, positioning PUR3100 as a Phase 2-ready asset. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.
  • The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in a peer-reviewed publication, Headache: The Journal of Head and Face Pain.
  • The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously (“IV”) administered DHE dose group.


PUR1800

  • PUR1800 is a Narrow Spectrum Kinase Inhibitor (“NSKI”), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease (“AECOPD”). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was safe and well tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.


PUR1900

  • PUR1900 is the Company’s inhaled iSPERSE™ formulation of the antifungal drug itraconazole for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need.
  • The Company completed all Phase 2b wind down activities in the third quarter of 2024. With the study wind down complete, Pulmatrix bears no further financial responsibility for the development of PUR1900.
  • The Company’s partner Cipla has continued clinical development outside the United States and has advised us that they have completed their Phase 2 study in India and have been approved by India’s Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial.
  • Should Cipla successfully market PUR1900 outside the United States, Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States. Within the United States, the Company and Cipla will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need.

Second Quarter 2025 Financial Results

Revenues decreased approximately $1.6 million to $0 for the three months ended June 30, 2025, compared to $1.6 million for the three months ended June 30, 2024. The decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical trial during the year ended December 31, 2024.

Research and development expenses decreased approximately $2.8 million to less than $0.1 million for the three months ended June 30, 2025, compared to $2.8 million for the three months ended June 30, 2024. The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company’s lab and facilities lease and employee terminations.

General and administrative expenses decreased approximately $0.5 million to $1.5 million for the three months ended June 30, 2025, compared to $2.0 million for the three months ended June 30, 2024. The decrease was primarily due to decreased employment and other operating costs, partially offset by incurred costs related to the proposed Merger.

The Company’s total cash and cash equivalents balance as of June 30, 2025, was $5.8 million. The Company anticipates that its cash position, based on operational efficiencies and prioritization of spending, is sufficient to fund its operations at least through the anticipated closing of the proposed Merger with Cullgen.

 


PULMATRIX, INC.


Consolidated Balance Sheets


(in thousands, except share and per share data)


June 30,


2025


December 31,


2024


(unaudited)


Assets

Current assets:

Cash and cash equivalents

$

5,825

$

9,521

Prepaid expenses and other current assets

317

399

Total current assets

6,142

9,920

Long-term restricted cash

10

10

Other long-term assets

13

Total assets

$

6,152

$

9,943


Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

384

$

809

Accrued expenses and other current liabilities

164

120

Total current liabilities

548

929

Warrant liability

67

Total liabilities

548

996

Stockholders’ equity:

Preferred Stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at June 30, 2025 and December 31, 2024

Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at June 30, 2025 and December 31, 2024

Additional paid-in capital

306,117

306,103

Accumulated deficit

(300,513)

(297,156)

Total stockholders’ equity

5,604

8,947

Total liabilities and stockholders’ equity

$

6,152

$

9,943

 


PULMATRIX, INC.


Consolidated Statements of Operations


(in thousands, except share and per share data)


(unaudited)


Three Months Ended


June 30,


Six Months Ended


June 30,


2025


2024


2025


2024


Revenues

$

$

1,552

$

$

7,437


Operating expenses:

Research and development

14

2,834

33

6,346

General and administrative

1,534

2,001

3,362

3,627

Loss on MannKind Transaction

2,618

2,618

Total operating expenses

1,548

7,453

3,395

12,591

Loss from operations

(1,548)

(5,901)

(3,395)

(5,154)


Other income (expense):

Interest income

41

133

94

293

Fair value adjustment of warrants

1

67

Other expense, net

(43)

(43)

(123)

(125)

Total other income (expense), net

(1)

90

38

168

Net loss

$

(1,549)

$

(5,811)

$

(3,357)

$

(4,986)

Net loss per share attributable to common stockholders – basic and diluted

$

(0.42)

$

(1.59)

$

(0.92)

$

(1.37)

Weighted average common shares outstanding – basic and diluted

3,652,285

3,652,285

3,652,285

3,652,285

About Pulmatrix, Inc.
Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.

About iSPERSE™ Technology
Pulmatrix’s innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies. iSPERSE™ is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs. iSPERSE™ can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.

For more on the Company’s inhaled product candidates please visit:
https://www.pulmatrix.com/pipeline.html.

Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of and the exact timing of the proposed Merger with Cullgen and satisfaction of closing conditions thereunder, among others; the Company’s ability to divest its clinical assets on terms favorable to the Company, or at all, the Company’s ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Chuck Padala

Managing Director
LifeSci Advisors
646-627-8390
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2025-financial-results-and-divestment-plan-for-inhalation-assets-302522900.html

SOURCE Pulmatrix Inc.

U.S. Soccer Federation and Kellanova Come Together to Celebrate the Team Spirit at the Heart of Soccer in New National Partnership

PR Newswire

This marks Kellanova North America’s first partnership in sports for its entire snack portfolio


ATLANTA and CHICAGO
, Aug. 6, 2025 /PRNewswire/ — Today, the U.S. Soccer Federation and Kellanova, a global snacking powerhouse, announced a partnership making Kellanova the Official Snack of U.S. Soccer. Together, they’ll unite under the rallying cry “It Takes a Pack” to celebrate the full team behind every soccer moment, from the elite athletes to the fans, families, coaches and communities that fuel the sport. 

Kellanova is partnering with U.S. Soccer at a pivotal moment for the sport, as the U.S. prepares to host some of the world’s most iconic soccer events. In 2026, the FIFA Men’s World Cup will be played across 11 U.S. cities, drawing billions of viewers worldwide. Just two years later, soccer will again take center stage during the 2028 Olympic Games in Los Angeles.

“Kellanova understands that soccer is more than a game, it’s a shared experience that brings people together,” said David Wright, Chief Commercial Officer, U.S. Soccer Federation. “This partnership is our way of celebrating the full soccer community, from the sidelines to the snack aisles. Together, we’re celebrating the players, parents, coaches and fans that surround and support soccer at every level.”

On and off the field, Kellanova has long been a trusted presence in the lives of soccer families and players of all ages. Now, Kellanova is elevating its support to the national stage, engaging with fans and athletes at men’s, women’s, youth, and more soccer events to create memorable and shareable moments within the game’s broad support system.

“The surge in U.S. soccer fandom—up 400% in first-time fans year-over-year—is more than a trend; it’s a movement,” said Nico Amaya, President of Kellanova North America. “This partnership gives Kellanova a unique opportunity to fuel national pride in this sport, drive portfolio growth and strengthen consumer connections with our brands. We’re proud to support the U.S. Soccer National Teams and to stand with the nation in celebrating the athletes and team spirit that define the sport.”

Fans can expect Kellanova’s brands to appear in national advertising, along with engaging digital and social media content and exclusive assets featuring the company’s iconic brand mascots. There will also be exciting retail activations, creative packaging, in-store displays and purpose-driven events in key soccer communities across the country.

“We’re proud to make soccer one of our next big bets to connect our brands to the heart of a growing community that thrives on passion, pride and the power of coming together,” said Julie Bowerman, Chief Marketing Officer of Kellanova North America. “We will continue to invest in sports because we see the value it brings—not only in growing fan engagement and cultural relevance, but also in delivering strong returns on our brand-building efforts.”

The partnership reflects U.S. Soccer’s deep commitment to community. Through Soccer Everywhere, one of its three strategic pillars, U.S. Soccer works to ensure everyone, everywhere can experience the joy of the game. This collaboration mirrors that mission, amplifying the everyday Most Valuable Players that make soccer thrive across the country.

About the U.S. Soccer Federation 

Founded in 1913, U.S. Soccer, a 501(c)(3) nonprofit, is the official governing body of the sport in the United States. Our vision is clear; we exist in service to soccer. Our ambition, working across the soccer ecosystem, is to ignite a national passion for the game.  We believe soccer is more than a sport; it is a force for good.  We are focused in three areas:  Soccer Everywhere, ensuring everyone, everywhere experiences the joy of soccer; Soccer Success, our 27 National Teams and pro leagues winning on the world stage; and Soccer Investment, maximizing and diversifying investments to sustainably grow the game at all levels.  For more information, visit ussoccer.com/ourvision

About Kellanova

Kellanova (NYSE: K) is a leader in global snacking, international cereal and noodles, and North America frozen foods with a legacy stretching back more than 100 years. Powered by differentiated brands including Pringles®, Cheez-It®, Pop-Tarts®, Kellogg’s ® Rice Krispies Treats®, RXBAR®, Eggo®, MorningStar Farms®, Special K® and more, Kellanova’s vision is to become the world’s best-performing snacks-led powerhouse, unleashing the full potential of our differentiated brands and our passionate people. Our net sales for 2024 were approximately $13 billion.

At Kellanova, our purpose is to create better days and ensure everyone has a seat at the table through our trusted food brands. We are committed to promoting sustainable and equitable food access by tackling the crossroads of hunger, sustainability, wellbeing, and equity, diversity & inclusion. Our goal is to create Better Days for 4 billion people by the end of 2030 (from a 2015 baseline). For more detailed information about our commitments, our approach to achieving these goals, and methodology, please visit our website at https://www.kellanova.com.

ussoccer.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/us-soccer-federation-and-kellanova-come-together-to-celebrate-the-team-spirit-at-the-heart-of-soccer-in-new-national-partnership-302522627.html

SOURCE Kellanova

Trinity Capital Inc. Reports Second Quarter 2025 Financial Results

PR Newswire

Total Investment Income grows 27.3% year-over-year

Net Asset Value reaches new high of $923.6 million

Return on Average Equity increases to 15.9%


PHOENIX
, Aug. 6, 2025 /PRNewswire/ — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity Capital” or “the Company”), a leading alternative asset manager, today announced its financial results for the second quarter ended June 30, 2025.

Second Quarter 2025 Highlights

  • Total investment income of $69.5 million, an increase of 27.3% year-over-year
  • Net investment income (“NII”) of $34.8 million, or $0.53 per basic share. NII grew 30.3% year over year.
  • Net increase in net assets resulting from operations of $41.4 million, or $0.63 per basic share
  • 15.9% Return on Average Equity “ROAE” (NII/Average Equity)
  • 7.2% Return on Average Assets “ROAA” (NII/Average Assets)
  • Net Asset Value (“NAV”) of $923.6 million, or $13.27 per share at the end of Q2. NAV increased 35.8% year over year.
  • Total gross investment commitments of $519.8 million
  • Total gross investments funded of $365.5 million, which was comprised of $292.3 million in 15 new portfolio companies and $73.2 million in 14 existing portfolio companies
  • Total investment exits and repayments of $195.0 million, including $109.3 million from early debt repayments and refinancings, $51.3 million from scheduled/amortizing debt payments, $34.2 million from investments sold to multi-sector holdings and $0.2 million from warrant and equity sales
  • 22nd consecutive quarter of a consistent or increased regular dividend, with a second quarter distribution of $0.51 per share

“Our second-quarter performance rounded out a solid first half of 2025, reflecting disciplined execution across our credit strategies and sustained demand from growth-oriented companies,” said Kyle Brown, Chief Executive Officer of Trinity Capital. “We enter the second half of 2025 with strong momentum in our direct lending businesses in addition to our RIA platform growth as we maintain a focus on delivering increasing value to our borrowers, partners, and investors.”

Second Quarter 2025 Operating Results

For the three months ended June 30, 2025, total investment income was $69.5 million, compared to $54.6 million for the three months ended June 30, 2024. The effective yield on the average debt investments at cost was 15.7% for the second quarter of 2025, compared to 16.0% for the second quarter of 2024. Effective yields generally include the effects of fees and income accelerations attributed to early loan repayments and other one-time events, and may also fluctuate quarter-to-quarter depending on the amount of prepayment activity.

Total operating expenses and excise taxes, excluding interest expense, for the second quarter of 2025 were $16.7 million, compared to $14.0 million during the second quarter of 2024. The increase was primarily attributable to higher compensation associated with additional headcount, an increase in professional fees, and higher G&A expenses offset by expenses allocated to the Company’s Registered Investment Adviser subsidiary.

Interest expense for the second quarter of 2025 was $18.0 million, compared to $13.9 million during the second quarter of 2024. The increase was primarily attributable to the increase in weighted average debt outstanding as well as borrowing rate.

Net investment income was approximately $34.8 million, or $0.53 per share based on 65.9 million basic weighted average shares outstanding for the second quarter of 2025, compared to $26.7 million or $0.53 per share for the second quarter of 2024 based on 50.2 million basic weighted average shares outstanding.

During the three months ended June 30, 2025, the Company’s net unrealized appreciation totaled approximately $14.9 million, which included net unrealized appreciation of $7.4 million from its warrant investments, net unrealized appreciation of $5.5 million from its equity investments, and net unrealized appreciation of $2.3 million from the Company’s debt investments. This is partially offset by $0.3 million  net unrealized depreciation attributable to foreign currency forward contracts.

Net realized loss on investments was approximately $8.3 million, primarily due to the workout of one secured loan.

Net increase in net assets resulting from operations was $41.4 million, or $0.63 per share, based on 65.9 million basic weighted average shares outstanding. This compares to a net increase in net assets resulting from operations of $30.8 million, or $0.61 per share, based on 50.2 million basic weighted average shares outstanding for the second quarter of 2024.

Net Asset Value

Total net assets at the end of the second quarter of 2025 increased by 10.8% to $923.6 million, compared to $833.4 million at the end of the first quarter of 2025. The increase in total net assets was primarily due to net portfolio performance, accretive ATM issuances, and net investment income exceeding the dividend declared. NAV per share increased to $13.27 per share in the second quarter from $13.05 per share as of March 31, 2025.

Portfolio and Investment Activity 

As of June 30, 2025, Trinity Capital’s investment portfolio had an aggregate fair value of approximately $1,978.3 million and was comprised of approximately $1,491.8 million in secured loans, $342.6 million in equipment financings, and $143.9 million in equity and warrants, across 163 portfolio companies. The Company’s debt portfolio is comprised of 81.4% first-lien loans and 18.6% second-lien loans, with 80% of the debt portfolio at floating rates based on principal outstanding.

During the second quarter, the Company originated approximately $519.8 million of total new commitments. Second quarter gross investments funded totaled approximately $365.5 million, which was comprised of $292.3 million of investments in 15 new portfolio companies and $73.2 million of investments in 14 existing portfolio companies. Gross investment fundings during the quarter for secured loans totaled $290.8 million, equipment financings totaled $66.5 million and warrant and equity investments totaled $8.2 million.

Proceeds received from exits and repayments of the Company’s investments during the second quarter totaled approximately $195.0 million, which included $109.3 million from early debt repayments and refinancings, $51.3 million from scheduled/amortizing debt payments, $34.2 million from investments sold to multi-sector holdings and $0.2 million from warrant and equity sales. The investment portfolio increased by $170.5 million on a cost basis, an increase of 9.3%, and $185.6 million on a fair value basis, an increase of 10.4% as compared to March 31, 2025.

As of the end of the second quarter, loans to three portfolio companies and equipment financings to one portfolio company were on non-accrual status with a total fair value of approximately $15.6 million, or 0.9% of the Company’s debt investment portfolio at fair value.

The following table shows the distribution of the Company’s loan and equipment financing investments on the 1 to 5 investment risk rating scale at fair value as of June 30, 2025 and March 31, 2025 (dollars in thousands):


June 30, 2025


March 31, 2025


Investment Risk Rating
Scale Range


 Designation


Investments at Fair
Value


Percentage
of Total
Portfolio


Investments at Fair
Value


Percentage
of Total
Portfolio

4.0 – 5.0

Very Strong Performance

$             97,881

5.3 %

$            92,956

5.6 %

3.0 – 3.9

Strong Performance

589,329

32.1 %

567,581

34.0 %

2.0 – 2.9

Performing

1,021,331

55.7 %

928,455

55.7 %

1.6 – 1.9

Watch

97,396

5.3 %

50,072

3.0 %

1.0 – 1.5

Default/Workout

15,601

0.9 %

15,156

0.9 %

Total Debt Investments excluding Senior Credit Corp 2022
LLC

1,821,538

99.3 %

1,654,220

99.2 %

Senior Credit Corp 2022 LLC (1)

12,885

0.7 %

12,885

0.8 %

Total Debt
Investments

$        1,834,423

100.0 %

$        1,667,105

100.0 %


_____________


(1) An investment risk rating is not applied to Senior Credit Corp 2022 LLC.

As of June 30, 2025, Trinity Capital’s loan and equipment financing investments had a weighted average risk rating score of 2.9, consistent with the score as of March 31, 2025. The Company’s grading scale is comprised of numerous factors, two key factors being liquidity and performance to plan. A company may be downgraded as it approaches the need for additional capital or if it is underperforming relative to its business plans. Conversely, it may be upgraded upon a capitalization event or if it is exceeding its plan. As such, the overall grading may fluctuate quarter-to-quarter.

Liquidity and Capital Resources 

As of June 30, 2025, the Company had approximately $143.3 million in available liquidity, including $26.3 million in unrestricted cash and cash equivalents. At the end of the period, the Company had approximately $117.0 million in available borrowing capacity under its KeyBank Credit Facility, subject to existing terms and advance rates and regulatory and covenant requirements. This excludes capital raised by the JV and funds managed by the Company’s wholly owned RIA subsidiary.

As of June 30, 2025, Trinity’s leverage, or debt-to-equity ratio, was approximately 115% as compared to 116% as of March 31, 2025.

During the three months ended June 30, 2025, Trinity utilized its equity ATM offering program to sell 5,717,121 million shares of its common stock at a weighted average price of $14.43 per share, raising $81.5 million of net proceeds.

During the three months ended June 30, 2025, Trinity utilized its debt ATM offering program and during the period issued and sold $2.2 million in aggregate principal amount of its March and September 2029 Notes.

Distributions 

On June 18, 2025, the Company’s Board of Directors declared a regular dividend totaling $0.51 per share with respect to the quarter ended June 30, 2025, which was paid on July 15, 2025, to stockholders of record as of June 30, 2025. The Board of Directors generally determines and announces the Company’s dividend distribution on a quarterly basis.

Recent Developments 

For the period from July 1, 2025 to August 4, 2025, the Company issued and sold 717,285 shares of its common stock at a weighted-average price of $14.32 per share and raised $10.2 million of net proceeds after deducting commissions to the sales agents on shares sold under the Equity ATM Program.

On July 3, 2025, the Company issued and sold $125.0 million in aggregate principal amount of its unsecured 6.750% Notes due 2030 (the “July 2030 Notes”) under its shelf Registration Statement on Form N-2. The proceeds were used to pay down a portion of the existing indebtedness outstanding under the KeyBank Credit Facility.

On July 8, 2025, the Company and certain of its affiliates were granted an exemptive relief order (the “Order”) from the SEC that permits the Company to enter into certain negotiated co-investment transactions alongside certain of its affiliates in a manner consistent with its investment objective, positions, policies, strategies, and restrictions as well as regulatory requirements and other pertinent factors, subject to compliance with the Order.

Conference Call 

Trinity Capital will hold a conference call to discuss its second quarter 2025 financial results at 12:00 p.m. Eastern Time on Wednesday, August 6, 2025.

To listen to the call, please dial (800) 267-6316, or (203) 518-9783 internationally, and reference Conference ID: TRINQ225 if asked, approximately 10 minutes prior to the start of the call.

A taped replay will be made available approximately two hours after the conclusion of the call and will remain available until August 13, 2025. To access the replay, please dial (800) 757-4761 or (402) 220-7215.

About Trinity Capital Inc.

Trinity Capital Inc. (NASDAQ: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $4.5 billion across over 400 investments since inception in 2008 (As of June 30, 2025). Headquartered in Phoenix, Arizona, Trinity Capital’s dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission (“SEC”). The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. More information on risks and other potential factors that could affect the Company’s financial results, including important factors that could cause actual results to differ materially from plans, estimates or expectations included herein or on the webcast/conference call, is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed annual report on Form 10-K and subsequent SEC filings.

 


TRINITY CAPITAL INC.

Consolidated Statements of Assets and Liabilities

(In thousands, except share and per share data)


June 30,


December 31,


2025


2024

(Unaudited)


ASSETS

Investments at fair value:

Control investments (cost of $103,725 and $82,391, respectively)

$

118,496

$

89,249

Affiliate investments (cost of $39,114 and $34,309, respectively)

39,227

34,727

Non-Control / Non-Affiliate investments (cost of $1,858,099 and $1,643,526,
respectively)

1,820,607

1,601,594

Total investments (cost of $2,000,938 and $1,760,226, respectively)

1,978,330

1,725,570

Cash and cash equivalents

26,251

9,627

Interest receivable

17,664

16,542

Deferred credit facility costs

5,870

6,586

Other assets

16,909

15,916


Total assets


$


2,045,024


$


1,774,241


LIABILITIES

KeyBank Credit Facility

$

483,000

$

113,000

Unsecured Notes, net of $8,523 and $10,327, respectively, of unamortized deferred
financing costs

569,808

764,673

Distribution payable

35,483

31,451

Security deposits

5,918

8,472

Accounts payable, accrued expenses and other liabilities

27,247

33,663


Total liabilities


1,121,456


951,259


NET ASSETS

Common stock, $0.001 par value per share (200,000,000 authorized, 69,574,146 and
61,669,059 shares issued and outstanding as of June 30, 2025 and
December 31, 2024, respectively)

70

62

Paid-in capital in excess of par

929,767

829,626

Distributable earnings/(accumulated deficit)

(6,269)

(6,706)


Total net assets


923,568


822,982


Total liabilities and net assets


$


2,045,024


$


1,774,241


NET ASSET VALUE PER SHARE


$


13.27


$


13.35

 


TRINITY CAPITAL INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)



Three Months Ended


Three Months Ended


Six Months Ended


Six Months Ended


June 30, 2025


June 30, 2024


June 30, 2025


June 30, 2024


INVESTMENT INCOME:

Interest and dividend income:

Control investments

$

2,430

$

783

$

4,758

$

1,635

Affiliate investments

977

474

2,250

859

Non-Control / Non-Affiliate investments

63,306

50,580

122,379

98,735

Total interest and dividend income

66,713

51,837

129,387

101,229

Fee and other income:

Affiliate investments

597

835

1,289

1,702

Non-Control / Non-Affiliate investments

2,173

1,969

4,192

2,163

Total fee and other income

2,770

2,804

5,481

3,865


Total investment income

69,483

54,641

134,868

105,094


EXPENSES:

Interest expense and other debt financing costs

18,044

13,885

35,700

26,029

Compensation and benefits

12,489

9,944

23,134

19,808

Professional fees

1,787

1,338

3,814

2,058

General and administrative

2,246

2,092

4,713

4,021

Total gross expenses

34,566

27,259

67,361

51,916

Allocated expenses to Trinity Capital Adviser, LLC

(508)

(916)


Total net expenses

34,058

27,259

66,445

51,916


NET INVESTMENT INCOME/(LOSS) BEFORE TAXES

35,425

27,382

68,423

53,178

Excise tax expense

621

639

1,238

1,278


NET INVESTMENT INCOME

34,804

26,743

67,185

51,900


NET REALIZED GAIN/(LOSS) FROM INVESTMENTS:

Control investments

(3,916)

(3,916)

Non-Control / Non-Affiliate investments

(8,262)

(2,572)

(10,416)

(1,220)


Net realized gain/(loss) from investments

(8,262)

(6,488)

(10,416)

(5,136)


NET CHANGE IN UNREALIZED
APPRECIATION/(DEPRECIATION) FROM INVESTMENTS:

Control investments

7,912

5,691

7,913

7,655

Affiliate investments

52

1,673

482

1,926

Non-Control / Non-Affiliate investments

6,908

3,209

3,335

(11,008)


Net change in unrealized appreciation/(depreciation) from investments

14,872

10,573

11,730

(1,427)


NET INCREASE/(DECREASE) IN NET ASSETS RESULTING
FROM OPERATIONS


$


41,414


$


30,828


$


68,499


$


45,337

NET INVESTMENT INCOME PER SHARE – BASIC


$


0.53


$


0.53


$


1.05


$


1.07

NET INVESTMENT INCOME PER SHARE – DILUTED


$


0.53


$


0.51


$


1.05


$


1.03

NET CHANGE IN NET ASSETS RESULTING FROM OPERATIONS
PER SHARE – BASIC


$


0.63


$


0.61


$


1.07


$


0.94

NET CHANGE IN NET ASSETS RESULTING FROM OPERATIONS
PER SHARE – DILUTED


$


0.63


$


0.59


$


1.07


$


0.90

WEIGHTED AVERAGE SHARES OUTSTANDING – BASIC


65,911,570


50,161,680


64,242,822


48,455,033

WEIGHTED AVERAGE SHARES OUTSTANDING – DILUTED


65,911,570


54,064,395


64,242,822


52,357,748

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-reports-second-quarter-2025-financial-results-302522319.html

SOURCE Trinity Capital Inc.

CrowdStrike Launches New Services to Secure AI Systems and Operationalize AI in the SOC

CrowdStrike Launches New Services to Secure AI Systems and Operationalize AI in the SOC

AI Systems Security Assessment and AI for SecOps Readiness expand CrowdStrike’s industry-leading AI Security Services portfolio, helping organizations reduce risk and stop breaches in the AI era

AUSTIN, Texas & LAS VEGAS–(BUSINESS WIRE)–Black Hat USA 2025 CrowdStrike (NASDAQ: CRWD) today announced two new expert-led offerings as part of its expanding AI Security Services portfolio: AI Systems Security Assessment and AI for SecOps Readiness. Expanding on CrowdStrike’s AI Red Team Services introduced in 2024, these services help organizations secure the AI systems powering modern business and safely integrate AI into security operations.

As organizations adopt LLMs, copilots, and agentic tools, they face a rapidly expanding attack surface with new risks such as shadow AI, misconfigurations, and autonomous agents acting as non-human identities operating with privileged access. At the same time, adversaries are using AI to automate reconnaissance, generate highly effective phishing content, and bypass traditional defenses. CrowdStrike’s new AI Security Services deliver expert-led guidance for operating securely in the AI era, helping organizations both secure AI and use AI to accelerate detection, response, and decision making across the SOC.

“Security teams are under pressure on both sides, to protect rapidly evolving AI systems and to bring AI into the SOC without introducing new risk,” said Tom Etheridge, chief global services officer, CrowdStrike. “These services are purpose-built to meet that dual challenge head-on, combining the power of the Falcon platform, threat intelligence, and expert guidance to help organizations reduce risk, improve resilience, and move faster with confidence.”

AI Systems Security Assessment

The AI Systems Security Assessment provides organizations with a clear understanding of how AI is being used across their environment, where risk exists, and how to strengthen governance and protections. Built on the foundation of CrowdStrike’s AI Red Team Services and Falcon® platform capabilities such as Falcon® Shield, Falcon Cloud Security AI-SPM, and AI Model Scanning, this new service brings technical depth and real-world insight into securing AI systems. Key capabilities include:

  • AI Risk Discovery Powered by Falcon: Provides real-time visibility into AI usage across SaaS, cloud, and endpoint environments – surfacing shadow AI, misconfigurations, and hidden exposure, including autonomous agents with privileged access, through Falcon-native telemetry.
  • Threat-informed AI Testing: Assesses model and system risk using internal benchmarking tools that emulate real-world adversary tactics.
  • Actionable AI Governance and Architecture Guidance: Delivers strategic recommendations to improve governance and secure the architecture for LLMs and agent-based systems – reducing risk and complexity across AI deployments.

AI for SecOps Readiness

The AI for SecOps Readiness service helps security teams safely and effectively use AI to operate at machine speed across detection, investigation, and response workflows. As adversaries accelerate with AI, defenders must modernize their operations to keep pace. This service helps organizations assess AI readiness, prioritize use cases, and develop a secure path to AI adoption. Key capabilities include:

  • SOC Readiness Assessment: Evaluates staffing, tooling, workflows, and governance to assess AI readiness across detection, investigation, and response.
  • Use Case Identification and Design: Pinpoints high-impact opportunities to apply AI – from alert triage to investigation – tailored to organizational maturity and operating environment.
  • Strategic Guidance and Architecture Planning: Includes reference architectures, integration strategies, and “build vs. buy” recommendations to support responsible, scalable AI adoption.
  • Actionable Roadmap for AI in the SOC: Delivers a prioritized integration plan for both Falcon-native and third-party AI tools – with clear guidance to reduce risk, streamline adoption, and drive operational outcomes.

To learn more about how CrowdStrike helps organizations secure AI systems and transform security operations, read our blog, visit us online, or stop by the CrowdStrike Black Hat booth #2733.

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | X | LinkedIn | Facebook | Instagram

Start a free trial today: https://www.crowdstrike.com/free-trial-guide/

© 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

Media Contact

Jake Schuster

CrowdStrike Corporate Communications

[email protected]

KEYWORDS: United States North America Texas Nevada

INDUSTRY KEYWORDS: Software Technology Artificial Intelligence Security

MEDIA:

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

  • ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3
  • ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta

SAN FRANCISCO–(BUSINESS WIRE)–
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated. ECLIPSE 3 is a Phase 2b trial designed to compare the combination of tobevibart and elebsiran to bulevirtide treatment in patients with CHD. ECLIPSE 3 will provide important supportive data to help establish access and reimbursement in key markets.

“People living with chronic hepatitis delta urgently need new options to treat their disease,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “With the strong foundation of our previous data and the proven expertise of our team, we believe our registrational ECLIPSE program will validate the potential of our combination of tobevibart and elebsiran to establish a new standard of care in both newly diagnosed and previously treated patients with chronic hepatitis delta.”

“We are encouraged by the high rates of viral suppression demonstrated by the combination of tobevibart and elebsiran in our Phase 2 SOLSTICE study,” said Mark Eisner, M.D., M.P.H., Chief Medical Officer, Vir Biotechnology. “Taken together, our ECLIPSE trials are designed to demonstrate the potential of our tobevibart and elebsiran combination therapy, including breadth of response and dosing convenience. These are key aspects for improving patients’ quality of life and supporting long-term treatment adherence in real-world settings.”

CHD is an area of significant unmet medical need, with no approved treatments in the U.S. and limited options globally. CHD is the most severe form of chronic viral hepatitis,1 with people living with the disease rapidly progressing to cirrhosis, liver failure2 and liver-related death.1 The objective of therapy is to eliminate the virus. Tobevibart in combination with elebsiran offers the potential to achieve this by tackling the viral lifecycle through multiple mechanisms.

The potential of the combination of tobevibart and elebsiran has been recognized by Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA), along with Priority Medicines (PRIME) and orphan drug status from the European Medicines Agency (EMA). These designations support the expedited development of treatments for serious diseases where there is a significant unmet medical need.

About the ECLIPSE Registrational Program

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the combination therapy in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (NCT06903338) is a Phase 3 trial evaluating the safety and efficacy of tobevibart in combination with elebsiran compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited. ECLIPSE 2 is a Phase 3 trial that will evaluate the efficacy and safety of switching to tobevibart and elebsiran in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 1 and 2 are designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies, and both trials are currently recruiting. ECLIPSE 3 is a Phase 2b head-to-head trial to evaluate tobevibart and elebsiran compared with bulevirtide in bulevirtide-naïve patients, and it is designed to provide important supportive data to help establish access and reimbursement in key markets.

ECLIPSE 3 plans to enroll participants who have never received bulevirtide for the treatment of CHD. Participants will be randomized 2:1 to receive the combination of tobevibart and elebsiran or bulevirtide. The primary endpoint in ECLIPSE 3 measures hepatitis delta virus (HDV) RNA at the lower limit of quantification target not detected, HDV RNA TND (defined as HDV RNA = 0 IU/mL), at Week 48.

About Tobevibart and Elebsiran

Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor’s Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta.

Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) discovered by Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicate that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

References:

1 WHO Hepatitis Delta Factsheet – Hepatitis D (who.int), accessed July 2025

2 CDC What is Hepatitis D – FAQ | CDC, accessed July 2025

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the therapeutic potential of the combination of tobevibart and elebsiran to treat CHD and Vir Biotechnology’s belief that it can establish a new standard of care in both newly diagnosed and previously treated patients with CHD; Vir Biotechnology’s clinical development plans and expectations for the ECLIPSE Phase 3 registrational program, including protocols for and enrollment into ongoing and planned clinical studies, target endpoints and data readouts; Vir Biotechnology’s strategy and plans; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology’s planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology’s competitors, as well as changes in expected or existing competition; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media

Corporate Communications, Vir Biotechnology

[email protected]

Investors

Richard Lepke

Senior Director, Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

CrowdStrike Signal Delivers the Next Evolution of AI-Powered Threat Detection

CrowdStrike Signal Delivers the Next Evolution of AI-Powered Threat Detection

Now GA, new self-learning detection engines surface threats undetectable for others – connecting subtle activity into prioritized leads to accelerate investigation, hunting, and response

AUSTIN, Texas–(BUSINESS WIRE)–
Black Hat USA 2025, Las Vegas — CrowdStrike (NASDAQ: CRWD) today announced the general availability of CrowdStrike Signal, a new class of AI-powered detection engines that surface the undetectable threats others miss – before they escalate. Signal uses self-learning models for every host to understand what’s normal in that environment across time, systems, and users. It pinpoints subtle, early-stage threat activity and connects related behaviors – before traditional tools act. By identifying weak signals that deviate from the norm and building high-confidence, prioritized leads, Signal accelerates the Falcon® platform’s AI advantage and empowers security teams to investigate, hunt, and stop threats earlier in the kill chain.

Modern attacks often begin with low-signal activity that appears benign in isolation. Traditional rule-based systems ignore these behaviors because they lack the context to tell what’s suspicious and what’s just noise. Even newer AI approaches apply scoring only after a detection has occurred.

Signal learns what’s normal across the environment and continuously updates its understanding of standard activity as conditions change – identifying what deviates and linking early-stage behaviors with downstream activity. By analyzing behavior earlier in the threat lifecycle and correlating subtle activity across time, CrowdStrike turns fragmented signals into a small number of prioritized, AI-generated leads that expose threats buried in the noise and jumpstart response. Born on the endpoint, Signal lays the foundation for next-generation detection across identity, cloud, and third-party data.

“CrowdStrike pioneered AI-native cybersecurity, and continues to deliver the innovation driving the industry forward. Signal is our latest breakthrough, built to detect how modern adversaries actually operate,” said Elia Zaitsev, chief technology officer, CrowdStrike. “Today’s attackers spread subtle signals over time to stay under the radar. Signal is designed to catch what others overlook, connecting the dots across systems and time to paint the full picture.”

Signal Through the Noise

Behind Signal is a new family of statistical time series models that analyze billions of daily events within each customer’s environment. By linking signals across time and systems, Signal filters out repetitive activity and surfaces what’s truly unusual. This correlation builds high-confidence patterns that reveal stealthy attacker behavior before others can, giving defenders a clear starting point to act.

  • Self-learning AI to Understand the Customer Environment: Signal continuously models behavior for each user, host, and process, adapting over time to surface meaningful deviations. Unlike static rules or pre-trained models, it delivers early-stage detection without manual configuration or constant adjustment.
  • Real-time Detection of Stealthy Tradecraft Others Miss: Signal links subtle behaviors often used by attackers – but also commonly seen on benign hosts – such as the use of living-off-the-land tools for reconnaissance or applications running from temporary directories. This low-signal activity may appear benign in isolation, but analyzed earlier, over time and context, it reveals attacker activity that would otherwise go unnoticed.
  • High-confidence Leads Reduce Alert Volume, Accelerate Response: Signal condenses a vast number of behaviors and detections into a small set of high-fidelity leads. It surfaces early indicators of compromise, reduces false positives, and groups related activity into a single starting point to eliminate manual triage and speed investigation, hunting, and response.

CrowdStrike Signal is now generally available. To learn more, read our blog or stop by the CrowdStrike Black Hat booth #2733.

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | X | LinkedIn | Facebook | Instagram

Start a free trial today: https://www.crowdstrike.com/free-trial-guide/

© 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

Media Contact:

Jake Schuster

CrowdStrike Corporate Communications

[email protected]

KEYWORDS: United States North America Texas Nevada

INDUSTRY KEYWORDS: Online Privacy Technology Security Nanotechnology Software Networks Robotics Data Management Artificial Intelligence

MEDIA:

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

  • VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMS
  • Amifampridine may be considered as a supportive care treatment
  • Guideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagnostic testing and treatment adoption

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.

The updated NCCN Clinical Practice Guidelines in Oncology for SCLC relating to LEMS now include symptom specificity—characterized by proximal muscle weakness and autonomic dysfunction. Under “Signs and Symptoms of Small Cell Lung Cancer” (SCL-A 2 of 2), the guidelines recommend diagnosis through a neurological evaluation, ideally in consultation with a neurologist, which may include testing for PQ- and N-type VGCC antibodies. Additionally, under “Principles of Supportive Care” (SCL-D), the guidelines recommend that amifampridine should be considered as a treatment in consultation with neurology.1

Approximately 50 percent of LEMS cases are associated with an underlying malignancy, most commonly SCLC. Literature suggests that LEMS is observed in 3 percent of SCLC patients. Based on an internal healthcare database analysis of SCLC claims, potentially 90 percent of LEMS patients with SCLC went undiagnosed. These undiagnosed LEMS patients may suffer from LEMS symptoms while undergoing treatment for SCLC.

“Early diagnosis of LEMS in SCLC is critical, as it may enable patients to have better outcomes if their LEMS symptoms are effectively treated while fighting SCLC. Accurate identification through VGCC antibody testing and comprehensive neurological evaluation is essential,” said William Andrews, MD, FACP, Chief Medical Officer, Catalyst. “The NCCN Guidelines are a trusted standard for guiding treatment decisions, and we believe this update will drive greater awareness. Ultimately, it will help patients, caregivers, and healthcare providers make more informed choices when addressing this serious unmet need.”


1NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To learn more about NCCN go to https://www.nccn.org/home/about

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.



Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]

Media Contact
David Schull, Russo Partners
(858) 717-2310
[email protected]

Natural Grocers® Celebrates Missouri Statehood Day with a Special Gift and Savings, August 10-12, 2025

PR Newswire

Missouri {N}power® members will receive a state-themed Natural Grocers reusable bag and a $5-off coupon from the family-operated grocer


LAKEWOOD, Colo.
, Aug. 6, 2025 /PRNewswire/ — Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its Celebrate Missouri Statehood Day event, August 10-12, at its seven Missouri stores. Customers are invited to celebrate Missouri Statehood Day with a free Natural Grocers reusable tote bag and a $5-off coupon for in-store purchases for all {N}power® members.


MISSOURI PROUD

Headquartered in Colorado,
Natural Grocers
expanded its roots to the state of Missouri, with its first store in Columbia in 2011. The company has since added six additional stores to serve Missourians in the “Show-Me State”, with the most recent being its Springfield store in 2021.


  1. Columbia
  2. Independence

  3. St. Joseph
  4. Liberty

  5. Joplin

  6. Jefferson City

  7. Springfield

“We’re proud to be a family-operated company with deep roots in the communities we serve,” said Raquel Isely, vice president of marketing for Natural Grocers. “When we began expanding outside of Colorado, Missouri stood out as a place where our values could truly take root. From the vibrant culture to the love of nature and community, the ‘Show-Me State’ has been a natural fit for everything we offer through our Five Founding Principles.

Nearly 14 years later, we’re grateful to continue serving health-conscious Missourians and to celebrate this special day with the communities that have welcomed us so warmly.”


MISSOURI {N}POWER® MEMBERS SAVE & CELEBRATE

Natural Grocers will be celebrating Missouri Statehood Day by honoring its customers with a freebie and extra savings for {N}power members from August 10 to August 12, 2025.


  • August 10-12:
    All {N}power members at Missouri stores will receive a FREE, limited-edition, reusable shopping bag featuring each of the 21 states Natural Grocers has a presence in—including Missouri, while supplies last.[i]

  • August 10-12:
    {N}power members will enjoy extra savings with a $5-off coupon.[ii]

SIGN UP & SAVE
Not an {N}power member? Not a problem! Discover {N}power, Natural Grocers’ free customer rewards program, and enjoy exclusive discounts, deals, and surprise offers. You’ll earn valuable rewards points with every visit. Customers can sign up for {N}power here.[iii] Customers can also download the Natural Grocers App for easy access to {N}power benefits and more. 

A COMMITMENT TO MISSOURI CREW:
Natural Grocers provides careers for approximately 125 good4usm Crew members in the state of Missouri. The company is passionate about ensuring that its employees can live a healthy, balanced life. Natural Grocers is committed to positively impacting Crew members’ physical, emotional and financial well-being with free nutrition education programs, excellent benefits and access to the highest quality, affordably priced products.

Click here to learn more about career options with Natural Grocers (search by store and state— including Missouri).

LEARN MORE

  • Subscribe to the Free Health Hotline® Magazine to learn more about a natural approach to living with monthly sale items, recipes and educational articles.
  • To keep up with the latest that Natural Grocers has to offer, follow them on Facebook, Instagram, TikTok or YouTube.
  • Click here for a complimentary media kit.
  • For media inquiries or sample requests, please email [email protected].

ABOUT NATURAL GROCERS BY VITAMIN COTTAGE
Founded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its Five Founding Principles—including its “Commitment to Community” and “Commitment to Crew”. In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit www.naturalgrocers.com for more information and store locations. 


[i]

Offer available only to {N}power® members. Limit one bag per customer. Offer valid 8/10/25-8/12/25 at participating Missouri stores, while supplies last. Quantity limited to stock on hand; no rain checks.


[ii]

Offer available only to {N}power members, for in store purchases at participating Missouri Natural Grocers stores, 8/10/25-8/12/25. Customer must load the reward via {N}power email or app prompt before shopping. $5 discount will be applied to product’s regular non-discounted price. A minimum purchase of $25 is required to use the $5-off coupon. Must present phone number at checkout to accumulate towards the $25 requirement in one transaction.  


[iii]

Sign up by 8/6/25 to receive this coupon via email or app. {N}power offers are available only to registered members and are subject to program terms and conditions available at www.naturalgrocers.com/npower and privacy available at www.naturalgrocers.com/privacy-policy. Natural Grocers reserves the right to correct errors. Void where prohibited by law. Natural Grocers employees, including members of their household, are not eligible.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/natural-grocers-celebrates-missouri-statehood-day-with-a-special-gift-and-savings-august-10-12-2025-302523136.html

SOURCE Natural Grocers by Vitamin Cottage, Inc.

Conduent Reports Second Quarter 2025 Financial Results

News from Conduent


Key Q2 2025 Highlights

  • Revenue and Adj. Revenue(1): $754M
  • Pre-tax Income (Loss): $(38)M
  • Adj. EBITDA Margin(1): 4.9%
  • New Business Signings ACV(2): $150M
  • Net ARR Activity Metric(2) (TTM): $63M

FLORHAM PARK, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions and services company, today announced its second quarter 2025 financial results.

Cliff Skelton, Conduent President and Chief Executive Officer, stated, “Q2 marks another quarter of progress on our journey. We exceeded expectations for Adjusted EBITDA and Adjusted EBITDA margin. Q2 Revenue was in line with guidance and while often affected by seasonality and economic conditions, was slightly higher sequentially. New business signings improved both year-over-year and sequentially, supported by a robust pipeline. Notably, our investments in technology platforms and client relationships are resulting in accelerated performance in our Transportation segment. Furthermore, government and legislative decisions may unlock additional opportunities for our Government segment. As we’ve shared previously, our portfolio rationalization efforts will continue and are expected to positively impact our margin and cash flow. These efforts also narrow the focus for our leaders, many of whom recently joined Conduent, bringing with them industry experience from well-regarded companies.”

Skelton continued, “We are pleased to welcome our new Chairman of the Board, Harsha Agadi, who, with his wealth of experience, assumes this role at a critical strategic juncture as we pivot to growth and address the next round of portfolio opportunities. We also extend our gratitude to Scott Letier for his several years as Chairman. Scott’s leadership and mentorship have been invaluable, and he will retain important positions on the Board going forward. Looking ahead, the Board and Management remain confident in our strategy, momentum and ability to execute.”


Key Financial Q2 2025 Results

($ in millions, except margin and per share data) Q2 2025 Q2 2024 Current
Quarter
Y/Y B/(W)
Revenue $754 $828 (8.9)%
Adjusted Revenue(1) $754 $774 (2.6)%
GAAP Net Income (Loss) $(40) $216 n/m
Adjusted EBITDA(1) $37 $24 54.2%
Adjusted EBITDA Margin(1) 4.9% 3.1% 180 bps
GAAP Income (Loss) Before Income Tax $(38) $300 n/m
GAAP Diluted EPS $(0.26) $1.07 n/m
Adjusted Diluted EPS(1) $(0.13) $(0.14) 7.1%
Cash Flow from Operating Activities $(15) $(41) 63.4%
Adjusted Free Cash Flow(1) $(30) $(55) 45.5%




Performance Commentary



Conduent’s liquidity position at the end of the quarter remained strong, and the $550 million revolving credit facility is largely undrawn.

Pre-tax income (loss) for the second quarter of 2025 was $(38) million versus $300 million in the prior year period. This decrease is primarily caused by the divestiture-driven gain on the transfer of the BenefitWallet portfolio and the sale of the Curbside Management and Public Safety businesses in the prior year period.

Q2 2025 Adjusted EBITDA of $37 million and Adjusted EBITDA Margin of 4.9% both increased versus the prior year period and exceeded expectations.

In the second quarter of 2025, Conduent repurchased approximately 2.7 million shares of common stock.


Additional Q2 2025 Performance Highlights

  • Expanded finance and procurement solutions leveraging Fairmarkit’s AI-Powered Technologies including GenAI. The collaboration is designed to optimize procurement workflows and complement Conduent’s FastCap® Finance Analytics, which improves financial performance by identifying cost-saving opportunities within procurement and spend management;
  • Implemented a technology feature that allows SNAP recipients to lock and unlock their EBT accounts using Conduent’s ConnectEBT mobile app and cardholder portal, giving beneficiaries greater control and helping to prevent fraud for a 12th U.S. state;
  • Named Supplier of the Year by General Motors for the fourth time, which recognizes global suppliers for their execution across key categories such as safety, innovation and resilience;
  • Recognized as a Leader in two 2025 NelsonHall Vendor Evaluation & Assessment Tools (NEAT) reviews focused on HR & Talent Transformation services for Benefits Administration & Experience-Led HR Transformation;
  • Named a Newsweek 2025 Top 100 Global Most Loved Workplace, marking Conduent’s third consecutive appearance among the Top 100 companies worldwide; and
  • Implemented a new EMV (Europay, Mastercard, and Visa) contactless fare collection system for Gestione Governativa Navigazione Laghi in Italy, one of the first EMV contactless systems deployed for boat transportation in the country.


FY 2025 Outlook

(3)

  FY 2024

Actuals
FY 2025

Outlook

(3)
     
Adj. Revenue

(1)
$3,176M $3,100M – $3,200M
     
Adj. EBITDA

(1)

/ Adj. EBITDA Margin

(1)
$124M / 3.9% 5.0% – 5.5%

(1) Refer to Appendix for definition and complete non-GAAP reconciliations of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS and Adjusted Free Cash Flow.

(2) Refer to Appendix for definition.

(3) Refer to Appendix for additional information regarding non-GAAP outlook.


Conference Call


Management will present the results during a conference call and webcast on August 6, 2025 at 9:00 a.m. ET.

The call will be available by live audio webcast along with the news release and online presentation slides at https://investor.conduent.com/.

The conference call will also be available by calling 877-407-4019 toll-free. If requested, the conference ID for this call is 13754400.

The international dial-in is 1-201-689-8337. The international conference ID is also 13754400.

A recording of the conference call will be available by calling 1-877-660-6853 three hours after the conference call concludes. The replay ID is 13754400.

The telephone recording will be available until Aug 20, 2025.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 53,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling approximately 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 13 million tolling transactions every day. Learn more at www.conduent.com.

Non-GAAP Financial Measures

We have reported our financial results in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). In addition, we have discussed our financial results using non-GAAP measures. We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Accordingly, we believe it is necessary to adjust several reported amounts, determined in accordance with U.S. GAAP, to exclude the effects of certain items as well as their related tax effects. Management believes that these non-GAAP financial measures provide an additional means of analyzing the results of the current period against the corresponding prior period. However, these non-GAAP financial measures should be viewed in addition to, and not as a substitute for, our reported results prepared in accordance with U.S. GAAP. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable U.S. GAAP measures and should be read only in conjunction with our Consolidated Financial Statements prepared in accordance with U.S. GAAP. Our management regularly uses our non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. Providing such non-GAAP financial measures to investors allows for a further level of transparency as to how management reviews and evaluates our business results and trends. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Compensation of our executives is based in part on the performance of our business based on certain of these non-GAAP measures. Refer to the “Non-GAAP Financial Measures” section attached to this release for a discussion of these non-GAAP measures and their reconciliation to the reported U.S. GAAP measures.

Forward-Looking Statements

This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “looking to continue,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” “as we progress,” “going to,” “path from here forward,” “think,” “path to deliver,” “from here,” “on track,” “remain” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements, including, but not limited to, statements regarding our financial results, condition and outlook; changes in our operating results; general market and economic conditions; and our projected financial performance, including all statements made under the section captioned “FY 2025 Outlook” within this release. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make.

Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to: government appropriations and termination rights contained in our government contracts, the competitiveness of the markets in which we operate and our ability to renew commercial and government contracts, including contracts awarded through competitive bidding processes; our ability to recover capital and other investments in connection with our contracts; our reliance on third-party providers; risk and impact of geopolitical events and increasing geopolitical tensions (such as the war in the Ukraine and conflict in the Middle East), macroeconomic conditions, natural disasters and other factors in a particular country or region on our workforce, customers and vendors; our ability to deliver on our contractual obligations properly and on time; changes in interest in outsourced business process services; claims of infringement of third-party intellectual property rights; our ability to estimate the scope of work or the costs of performance in our contracts; the loss of key senior management and our ability to attract and retain necessary technical personnel and qualified subcontractors; our failure to develop new service offerings and protect our intellectual property rights; our ability to modernize our information technology infrastructure and consolidate data centers; expectations relating to environmental, social and governance considerations; utilization of our stock repurchase program; risks related to our use of artificial intelligence; the failure to comply with laws relating to individually identifiable information and personal health information; the failure to comply with laws relating to processing certain financial transactions, including payment card transactions and debit or credit card transactions; breaches of our information systems or security systems or any service interruptions; risks related to hacking or other cybersecurity threats to our data systems, information systems and network infrastructure and other service interruptions, including relating to the previously disclosed cyber event that took place in January 2025, including Conduent’s investigation of such incident and mitigation and remediation efforts, the nature and extent of such incident, the potential disruption to our business or operations, the potential impact on Conduent’s reputation, and Conduent’s assessments of the likely financial and operational impacts of such incident; our ability to comply with data security standards; developments in various contingent liabilities that are not reflected on our balance sheet, including those arising as a result of being involved in a variety of claims, lawsuits, investigations and proceedings; risks related to recently completed divestitures including (i) the transfer of the Company’s BenefitWallet’s health savings account, medical savings account and flexible spending account portfolio, (ii) the sale of the Company’s Curbside Management and Public Safety Solutions businesses and (iii) the sale of the Company’s Casualty Claims Solutions business, including but not limited to the Company’s ability to realize the benefits anticipated from such transactions, unexpected costs, liabilities or delays in connection with such transactions, and the significant transaction costs associated with such transactions; risk and impact of potential goodwill and other asset impairments; our significant indebtedness and the terms of such indebtedness; our failure to obtain or maintain a satisfactory credit rating and financial performance; our ability to obtain adequate pricing for our services and to improve our cost structure; our ability to collect our receivables, including those for unbilled services; a decline in revenues from, or a loss of, or a reduction in business from or failure of significant clients; fluctuations in our non-recurring revenue; increases in the cost of voice and data services or significant interruptions in such services; our ability to receive dividends or other payments from our subsidiaries; and other factors that are set forth in the “Risk Factors” section, the “Legal Proceedings” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other sections in our 2024 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.

Media Contacts:

Sean Collins, Conduent, +1-310-497-9205, [email protected]

Investor Contacts:

David Chen, Conduent, [email protected]



CONDUENT INCORPORATED


CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (UNAUDITED)

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions, except per share data)     2025       2024       2025       2024  
Revenue   $ 754     $ 828     $ 1,505     $ 1,749  
                 
Operating Costs and Expenses                
Cost of services (excluding depreciation and amortization)     617       677       1,235       1,412  
Selling, general and administrative (excluding depreciation and amortization)     100       115       220       231  
Research and development (excluding depreciation and amortization)     1       1       2       3  
Depreciation and amortization     48       51       96       113  
Restructuring and related costs     8       8       12       17  
Interest expense     12       19       24       46  
(Gain) loss on divestitures and transaction costs, net     4       (347 )     7       (508 )
Litigation settlements (recoveries), net           1       2       5  
Loss on extinguishment of debt           3             5  
Other (income) expenses, net     2             1       (2 )
Total Operating Costs and Expenses     792       528       1,599       1,322  
                 
Income (Loss) Before Income Taxes     (38 )     300       (94 )     427  
                 
Income tax expense (benefit)     2       84       (3 )     112  
Net Income (Loss)   $ (40 )   $ 216     $ (91 )   $ 315  
                 
Net Income (Loss) per Share:                
Basic   $ (0.26 )   $ 1.10     $ (0.59 )   $ 1.54  
Diluted   $ (0.26 )   $ 1.07     $ (0.59 )   $ 1.51  

CONDUENT INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions)     2025       2024       2025       2024  
Net Income (Loss)   $ (40 )   $ 216     $ (91 )   $ 315  
Other Comprehensive Income (Loss), Net

(1)
               
Currency translation adjustments, net     24       (16 )     33       (27 )
Unrecognized gains (losses), net           (1 )     2       (1 )
Other Comprehensive Income (Loss), Net     24       (17 )     35       (28 )
                 
Comprehensive Income (Loss), Net   $ (16 )   $ 199     $ (56 )   $ 287  



(1)   

All amounts are net of tax. Tax effects were immaterial.

CONDUENT INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in millions, except share data in thousands)   June 30, 2025   December 31, 2024
Assets        
Cash and cash equivalents   $ 275     $ 366  
Accounts receivable, net     458       493  
Contract assets     138       132  
Other current assets     276       261  
Total current assets     1,147       1,252  
Land, buildings and equipment, net     182       167  
Operating lease right-of-use assets     159       169  
Intangible assets, net     13       14  
Goodwill     617       609  
Other long-term assets     370       388  
Total Assets   $ 2,488     $ 2,599  
Liabilities and Equity        
Current portion of long-term debt   $ 28     $ 24  
Accounts payable     126       157  
Accrued compensation and benefits costs     168       170  
Unearned income     80       103  
Other current liabilities     295       290  
Total current liabilities     697       744  
Long-term debt     628       615  
Deferred taxes     16       24  
Operating lease liabilities     127       138  
Other long-term liabilities     101       93  
Total Liabilities     1,569       1,614  
         
Series A convertible preferred stock     142       142  
         
Common stock     2       2  
Treasury stock, at cost     (218 )     (210 )
Additional paid-in capital     3,959       3,952  
Retained earnings (deficit)     (2,529 )     (2,433 )
Accumulated other comprehensive loss     (437 )     (472 )
Total Conduent Inc. Equity     777       839  
Noncontrolling Interest           4  
Total Equity     777       843  
Total Liabilities and Equity   $ 2,488     $ 2,599  
         
Shares of common stock issued and outstanding     159,157       161,829  
Shares of series A convertible preferred stock issued and outstanding     120       120  
Shares of common stock held in treasury     63,550       60,868  

CONDUENT INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions)     2025       2024       2025       2024  
Cash Flows from Operating Activities:                
Net income (loss)   $ (40 )   $ 216     $ (91 )   $ 315  
Adjustments required to reconcile net income (loss) to cash flows from operating activities:                
Depreciation and amortization     48       51       96       113  
Contract inducement amortization     1             1       1  
Deferred income taxes     1       5       (7 )     18  
Amortization of debt financing costs     1       1       1       2  
Loss on extinguishment of debt           3             5  
(Gain) loss on divestitures and sales of fixed assets, net     2       (369 )     2       (533 )
Stock-based compensation     5       5       8       8  
Changes in operating assets and liabilities     (23 )     (12 )     (71 )     (103 )
Net change in income tax assets and liabilities     (10 )     59       (12 )     96  
Net cash provided by (used in) operating activities     (15 )     (41 )     (73 )     (78 )
Cash Flows from Investing Activities:                
Cost of additions to land, buildings and equipment     (15 )     (18 )     (29 )     (31 )
Cost of additions to internal use software     (5 )     (7 )     (9 )     (15 )
Proceeds from divestitures     52       435       53       599  
Net cash provided by (used in) investing activities     32       410       15       553  
Cash Flows from Financing Activities:                
Proceeds from revolving credit facility     75       30       125       30  
Proceeds from the issuance of debt, net     4             4        
Payments on revolving credit facility     (75 )     (30 )     (125 )     (30 )
Payments on debt     (7 )     (328 )     (15 )     (503 )
Treasury stock purchases     (7 )     (151 )     (7 )     (168 )
Excise tax payment on treasury stock purchases     (2 )           (2 )      
Taxes paid for settlement of stock-based compensation                       (5 )
Dividends paid on preferred stock     (3 )     (3 )     (5 )     (5 )
Repurchase of noncontrolling interest     (5 )           (5 )      
Net cash provided by (used in) financing activities     (20 )     (482 )     (30 )     (681 )
Effect of exchange rate changes on cash, cash equivalents and restricted cash     4       (4 )     5       (6 )
Increase (decrease) in cash, cash equivalents and restricted cash     1       (117 )     (83 )     (212 )
Cash, Cash Equivalents and Restricted Cash at Beginning of Period     293       424       377       519  
Cash, Cash Equivalents and Restricted Cash at End of period

(1)
  $ 294     $ 307     $ 294     $ 307  

(1) Includes
$19 million
and
$7 million
restricted cash as of
June 30, 2025
and
2024
, respectively, that were included in Other current assets on the respective Condensed Consolidated Balance Sheets.



Appendix


Definitions

Net ARR Activity Metric (TTM)

Projected Annual Recurring Revenue (ARR) for contracts signed in the prior 12 months, less the annualized impact of any client losses, contractual volume and price changes, and other known impacts for which the Company was notified in that same time period, which could positively or negatively impact results. The metric annualizes the net impact to revenue. Timing of revenue impact varies and may not be realized within the forward 12-month timeframe. The metric is for indicative purposes only. This metric excludes non-recurring revenue signings. This metric is not indicative of any specific 12 month timeframe.

New Business Annual Contract Value (ACV): (New Business TCV / contract term) multiplied by 12.

New Business Total Contract Value (TCV): Estimated total future revenues from contracts signed during the period related to new logo, new service line or expansion with existing customers.

TTM: Trailing twelve months.

PBT: Profit before tax.


Non-GAAP Financial Measures

We have reported our financial results in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). In addition, we have discussed our financial results using non-GAAP measures.

We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Accordingly, we believe it is necessary to adjust several reported amounts, determined in accordance with U.S. GAAP, to exclude the effects of certain items as well as their related tax effects. Management believes that these non-GAAP financial measures provide an additional means of analyzing the results of the current period against the corresponding prior period. However, these non-GAAP financial measures should be viewed in addition to, and not as a substitute for, the Company’s reported results prepared in accordance with U.S. GAAP. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable U.S. GAAP measures and should be read only in conjunction with our Consolidated Financial Statements prepared in accordance with U.S. GAAP. Our management regularly uses our non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions, and providing such non-GAAP financial measures to investors allows for a further level of transparency as to how management reviews and evaluates our business results and trends. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Compensation of our executives is based in part on the performance of our business based on certain of these non-GAAP measures.

Management cautions that amounts presented in accordance with Conduent’s definition of non-GAAP financial measures may not be comparable to similar measures disclosed by other companies because not all companies calculate non-GAAP measures in the same manner.

A reconciliation of the following non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP are provided below.

These reconciliations also include the income tax effects for our non-GAAP performance measures in total, to the extent applicable. The income tax effects are calculated under the same accounting principles as applied to our reported pre-tax performance measures under Accounting Standards Codification 740, which employs an annual effective tax rate method. The noted income tax effect for our non-GAAP performance measures is effectively the difference in income taxes for reported and adjusted pre-tax income calculated under the annual effective tax rate method. The tax effect of the non-GAAP adjustments was calculated based upon evaluation of the statutory tax treatment and the applicable statutory tax rate in the jurisdictions in which such charges were incurred.

Adjusted Revenue, Adjusted Profit Before Tax, Adjusted Net Income (Loss), Adjusted Diluted Earnings per Share, Adjusted Weighted Average Common Shares Outstanding, and Adjusted Effective Tax Rate

We make adjustments to Revenue, Net Income (Loss) before Income Taxes for the following items, as applicable, to the particular financial measure, for the purpose of calculating Adjusted Revenue, Adjusted Profit Before Tax, Adjusted Net Income (Loss), Adjusted Diluted Earnings per Share, Adjusted Weighted Average Common Shares Outstanding, and Adjusted Effective Tax Rate:

  • Amortization of acquired intangible assets. This is driven by acquisition activity, which can vary in size, nature and timing as compared to other companies within our industry and from period to period.
  • Restructuring and related costs. This includes restructuring and asset impairment charges as well as costs associated with our strategic transformation program.
  • Goodwill impairment. This represents goodwill impairment charges arising from annual or interim goodwill testing.
  • (Gain) loss on divestitures and transaction costs, net. Represents (gain) loss on divested businesses and transaction costs.
  • Litigation settlements (recoveries), net represents settlements or recoveries for various matters subject to litigation.
  • Loss on extinguishment of debt. This represents write-off related debt issuance costs related to prepayments of debt.
  • Direct response costs – cyber event. This represents costs related to investigating, remediating and responding to the cyber event that occurred in January 2025.
  • Other charges (credits). This includes Other (income) expenses, net on the Consolidated Statements of Income (loss) and other adjustments.
  • Divestitures. Revenue and Adjusted EBITDA of divested businesses are excluded.

The Company provides adjusted net income and adjusted EPS financial measures to assist our investors in evaluating our ongoing operating performance for the current reporting period and, where provided, over different reporting periods, by adjusting for certain items which may be recurring or non-recurring and which in our view do not necessarily reflect ongoing performance. We also internally use these measures to assess our operating performance, both absolutely and in comparison to other companies, and in evaluating or making selected compensation decisions.

Management believes that the adjusted effective tax rate, provided as supplemental information, facilitates a comparison by investors of our actual effective tax rate with an adjusted effective tax rate which reflects the impact of the items which are excluded in providing adjusted net income and certain other identified items, and may provide added insight into our underlying business results and how effective tax rates impact our ongoing business.

Adjusted Revenue, Adjusted Operating Income and Adjusted Operating Margin

We make adjustments to Revenue, Costs and Expenses and Operating Margin for the following items, as applicable, for the purpose of calculating Adjusted Revenue, Adjusted Operating Income and Adjusted Operating Margin:

  • Amortization of acquired intangible assets.
  • Restructuring and related costs.
  • Interest expense. Interest expense includes interest on long-term debt and amortization of debt issuance costs.
  • Goodwill impairment.
  • (Gain) loss on divestitures and transaction costs, net.
  • Litigation settlements (recoveries), net.
  • Loss on extinguishment of debt.
  • Direct response costs – cyber event.
  • Other charges (credits).
  • Divestitures.

We provide our investors with adjusted revenue, adjusted operating income and adjusted operating margin information, as supplemental information, because we believe it offers added insight, by itself and for comparability between periods, by adjusting for certain non-cash items as well as certain other identified items which we do not believe are indicative of our ongoing business, and may also provide added insight on trends in our ongoing business.

Adjusted EBITDA and EBITDA Margin

We use Adjusted EBITDA and Adjusted EBITDA Margin as an additional way of assessing certain aspects of our operations that, when viewed with the U.S. GAAP results and the accompanying reconciliations to corresponding U.S. GAAP financial measures, provide a more complete understanding of our on-going business. Adjusted EBITDA represents income (loss) before interest, income taxes, depreciation and amortization and contract inducement amortization adjusted for the following items. Adjusted EBITDA Margin is Adjusted EBITDA divided by revenue or adjusted revenue, as applicable.

  • Restructuring and related costs.
  • Goodwill impairment.
  • (Gain) loss on divestitures and transaction costs, net.
  • Litigation settlements (recoveries), net.
  • Loss on extinguishment of debt.
  • Direct response costs – cyber event.
  • Other charges (credits).
  • Divestitures.

Adjusted EBITDA is not intended to represent cash flows from operations, operating income (loss) or net income (loss) as defined by U.S. GAAP as indicators of operating performance.

Free Cash Flow

Free Cash Flow is defined as cash flows from operating activities as reported on the consolidated statement of cash flows, less cost of additions to land, buildings and equipment, cost of additions to internal use software, and proceeds from sales of land, buildings and equipment, as applicable. We use the non-GAAP measure of Free Cash Flow as a criterion of liquidity. We use Free Cash Flow as a measure of liquidity to determine amounts we can reinvest in our core businesses, such as amounts available to make acquisitions and invest in land, buildings and equipment and internal use software, after required payments on debt. In order to provide a meaningful basis for comparison, we are providing information with respect to our Free Cash Flow reconciled to cash flow provided by operating activities, which we believe to be the most directly comparable measure under U.S. GAAP.

Adjusted Free Cash Flow

Adjusted Free Cash Flow is defined as Free Cash Flow from above plus adjustments for litigation insurance recoveries, transaction costs, taxes paid on gains from divestitures and litigation recoveries, proceeds from failed sale-leaseback transactions and certain other identified adjustments, as applicable. We use Adjusted Free Cash Flow, in addition to Free Cash Flow, to provide supplemental information to our investors concerning our ability to generate cash from our ongoing operating activities; by excluding these items, we believe we provide useful additional information to our investors to help them further understand our ability to generate cash period-over-period as well as added information on comparability to our competitors. Such as with Free Cash Flow information, as so adjusted, it is specifically not intended to provide amounts available for discretionary spending. We have added certain adjustments to account for items which we do not believe reflect our core business or operating performance, and we computed all periods with such adjusted costs.

Revenue at Constant Currency

To better understand trends in our business, we believe that it is helpful to adjust revenue to exclude the impact of changes in the translation of foreign currencies into U.S. Dollars. We refer to this adjusted revenue as “constant currency.” Currency impact is determined as the difference between actual growth rates and constant currency growth rates. This currency impact is calculated by translating the current period activity in local currency using the comparable prior-year period’s currency translation rate.

Non-GAAP Outlook

In providing the Full Year 2025 outlook for Adjusted EBITDA and Adjusted EBITDA Margin we exclude certain items which are otherwise included in determining the comparable U.S. GAAP financial measure. A description of the adjustments which historically have been applicable in determining Adjusted EBITDA and Adjusted EBITDA Margin is reflected in the table below. We are providing such outlook only on a non-GAAP basis because the Company is unable without unreasonable efforts to predict with reasonable certainty the totality or ultimate outcome or occurrence of these adjustments for the forward-looking period, which can be dependent on future events that may not be reliably predicted. Based on past reported results, where one or more of these items have been applicable, such excluded items could be material, individually or in the aggregate, to reported results. We have provided an outlook for Adjusted Revenue only on a non-GAAP basis using foreign currency translation rates as of fiscal year end due to the inability to, without unreasonable efforts, accurately predict foreign currency impact on revenues.

Non-GAAP Reconciliations: Adjusted Revenue, Revenue at Constant Currency, Adjusted Net Income (Loss), Adjusted Effective Tax, Adjusted Operating Income (Loss) and Adjusted EBITDA were as follows (see footnotes on last page of Non-GAAP reconciliations):

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions)     2025       2024       2025       2024  

ADJUSTED REVENUE
               
Revenue   $ 754     $ 828     $ 1,505     $ 1,749  
Adjustment:                
Divestitures(1)           (54 )           (154 )
Adjusted Revenue     754       774       1,505       1,595  
Foreign currency impact     (1 )     1       3       (1 )
Revenue at Constant Currency   $ 753     $ 775     $ 1,508     $ 1,594  
                 

ADJUSTED NET INCOME (LOSS)
               
Net Income (Loss)   $ (40 )   $ 216     $ (91 )   $ 315  
Adjustments:                
Amortization of acquired intangible assets(2)     1       2       1       3  
Restructuring and related costs     8       8       12       17  
Loss on extinguishment of debt           3             5  
(Gain) loss on divestitures and transaction costs, net     4       (347 )     7       (508 )
Litigation settlements (recoveries), net           1       2       5  
Direct response costs – cyber event                 25        
Other charges (credits)     2             1       (2 )
Total Non-GAAP Adjustments     15       (333 )     48       (480 )
Income tax adjustments(3)     7       92       7       124  
Adjusted Net Income (Loss) Before Adjustment for Divestitures     (18 )     (25 )     (36 )     (41 )
Divestitures(1)           (8 )           (32 )
Adjusted Net Income (Loss)   $ (18 )   $ (33 )   $ (36 )   $ (73 )
                 
                 

ADJUSTED EFFECTIVE TAX
               
Income (Loss) Before Income Taxes   $ (38 )   $ 300     $ (94 )   $ 427  
Adjustments:                
Total Non-GAAP Adjustments     15       (333 )     48       (480 )
Adjusted PBT Before Adjustment for Divestitures     (23 )     (33 )     (46 )     (53 )
Divestitures(1)           (8 )           (32 )
Adjusted PBT   $ (23 )   $ (41 )   $ (46 )   $ (85 )
                 
Adjusted PBT Before Adjustment for Divestitures     (23 )     (33 )     (46 )     (53 )
Adjustments:                
Income tax expense (benefit)   $ 2     $ 84     $ (3 )   $ 112  
Income tax adjustments(3)     (7 )     (92 )     (7 )     (124 )
Adjusted Income Tax Expense (Benefit)     (5 )     (8 )     (10 )     (12 )
Adjusted Net Income (Loss) Before Adjustment for Divestitures     (18 )     (25 )     (36 )     (41 )
Divestitures(1)           (8 )           (32 )
Adjusted Net Income (Loss)   $ (18 )   $ (33 )   $ (36 )   $ (73 )

CONTINUED   Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions)     2025       2024       2025       2024  

ADJUSTED OPERATING INCOME (LOSS)
               
Income (Loss) Before Income Taxes   $ (38 )   $ 300     $ (94 )   $ 427  
Adjustments:                
Total non-GAAP adjustments     15       (333 )     48       (480 )
Interest expense     12       19       24       46  
Adjusted Operating Income (Loss) Before Adjustment for Divestitures     (11 )     (14 )     (22 )     (7 )
Divestitures(1)           (8 )           (32 )
Adjusted Operating Income (Loss)   $ (11 )   $ (22 )   $ (22 )   $ (39 )
                 

ADJUSTED EBITDA
               
Net Income (Loss)   $ (40 )   $ 216     $ (91 )   $ 315  
Income tax expense (benefit)     2       84       (3 )     112  
Depreciation and amortization     48       51       96       113  
Contract inducement amortization     1             1       1  
Interest expense     12       19       24       46  
EBITDA Before Adjustment for Divestitures     23       370       27       587  
Divestitures(1)           (8 )           (32 )
Divestitures depreciation and amortization(1)           (3 )           (12 )
EBITDA     23       359       27       543  
Adjustments:                
Restructuring and related costs     8       8       12       17  
(Gain) loss on divestitures and transaction costs, net     4       (347 )     7       (508 )
Litigation settlements (recoveries), net           1       2       5  
Loss on extinguishment of debt           3             5  
Direct response costs – cyber event                 25        
Other charges (credits)     2             1       (2 )
Adjusted EBITDA   $ 37     $ 24     $ 74     $ 60  



Non-GAAP Reconciliations:
Adjusted Weighted Average Shares Outstanding, Adjusted Diluted EPS, Adjusted Effective Tax Rate, Adjusted Operating Margin and Adjusted EBITDA Margin were as follows:

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(Amounts are in whole dollars, shares are in thousands and margins and rates are in %)     2025       2024       2025       2024  

ADJUSTED DILUTED EPS


(4)
               
Weighted Average Common Shares Outstanding     161,162       194,539       161,448       201,159  
Adjustments:                
Restricted stock and performance units / shares                        
Adjusted Weighted Average Common Shares Outstanding     161,162       194,539       161,448       201,159  
                 
Diluted EPS from Continuing Operations   $ (0.26 )   $ 1.07     $ (0.59 )   $ 1.51  
Adjustments:                
Total non-GAAP adjustments     0.09       (1.68 )     0.30       (2.36 )
Income tax adjustments(3)     0.04       0.47       0.04       0.62  
Adjusted Diluted EPS   $ (0.13 )   $ (0.14 )   $ (0.25 )   $ (0.23 )
                 

ADJUSTED EFFECTIVE TAX RATE
               
Effective tax rate     (5.7 )%     28.2  %     3.1  %     26.3  %
Adjustments:                
Total non-GAAP adjustments     26.2  %     (4.6 )%     19.2  %     (3.2 )%
Adjusted Effective Tax Rate

(3)
    20.5  %     23.6  %     22.3  %     23.1  %
                 

ADJUSTED OPERATING MARGIN
               
Income (Loss) Before Income Taxes Margin     (5.0 )%     36.2  %     (6.2 )%     24.4  %
Adjustments:                
Total non-GAAP adjustments     1.9  %     (40.2 )%     3.1  %     (27.4 )%
Interest expense     1.6  %     2.3  %     1.6  %     2.6  %
Margin for Adjusted Operating Income Before Adjustment for Divestitures     (1.5 )%     (1.7 )%     (1.5 )%     (0.4 )%
Divestitures(1)      %     (1.1 )%      %     (2.0 )%
Margin for Adjusted Operating Income     (1.5 )%     (2.8 )%     (1.5 )%     (2.4 )%


ADJUSTED EBITDA MARGIN
               
EBITDA Margin Before Adjustment for Divestitures   3.1  %   44.7  %   1.8  %   33.6  %
Adjustments:                
Divestitures(1)    %   1.7  %    %   0.4  %
EBITDA Margin   3.1  %   46.4  %   1.8  %   34.0  %
Total non-GAAP adjustments   1.8  %   (40.5 )%   3.1  %   (27.7 )%
Divestitures(1)    %   (1.7 )%    %   (0.4 )%
Adjusted EBITDA Margin Before Adjustment for Divestitures   4.9  %   4.2  %   4.9  %   5.9  %
Divestitures(1)    %   (1.1 )%    %   (2.1 )%
Adjusted EBITDA Margin   4.9  %   3.1  %   4.9  %   3.8  %



Free Cash Flow and Adjusted Free Cash Flow Reconciliation:

    Three Months Ended
June 30,
  Six Months Ended
June 30,
(in millions)     2025       2024       2025       2024  
Operating Cash Flow   $ (15 )   $ (41 )   $ (73 )   $ (78 )
Cost of additions to land, buildings and equipment     (15 )     (18 )     (29 )     (31 )
Cost of additions to internal use software     (5 )     (7 )     (9 )     (15 )
Free Cash Flow   $ (35 )   $ (66 )   $ (111 )   $ (124 )
Free Cash Flow   $ (35 )   $ (66 )   $ (111 )   $ (124 )
Transaction costs     3       8       7       11  
Direct response costs – cyber event payments                 2        
Vendor finance lease payments     (3 )     (4 )     (7 )     (9 )
Proceeds from failed sale-leaseback transactions     5             5        
Tax payment related to divestitures and litigation recoveries           7             7  
Adjusted Free Cash Flow   $ (30 )   $ (55 )   $ (104 )   $ (115 )

(1) Adjusted for the full impact from revenue and income/loss from divestitures for all periods presented.
(2) Included in Depreciation and amortization on the Consolidated Statements of Income (Loss).
(3) The tax impact of Adjusted Pre-tax income (loss) was calculated under the same accounting principles applied to the ‘As Reported’ pre-tax income (loss), which employs an annual effective tax rate method to the results and without regard to the Total Non-GAAP adjustments.
(4) Average shares for the 2025 and 2024 calculation of adjusted EPS excludes 5.4 million shares associated with our Series A convertible preferred stock and includes the impact of preferred stock dividends of approximately $3 million each quarter.